Inhibikase Therapeutics (IKT) Common Equity (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Common Equity data on file, last reported at $167.6 million in Q1 2026.

• On a quarterly basis, Common Equity rose 95.52% year-over-year to $167.6 million in Q1 2026; TTM through Mar 2026 was $167.6 million, a 95.52% increase from a year earlier, with the FY2025 full-year figure at $172.9 million, up 82.26% from the prior year.
• Common Equity for Q1 2026 stood at $167.6 million, down from $172.9 million in the prior quarter.
• Over the last five years, Common Equity for IKT reached as high as $172.9 million in Q4 2025 and fell as low as -$530591.0 in Q3 2024.
• Historically, Common Equity has averaged $50.9 million across 5 years, with a median of $25.3 million in 2023.
• Across the five-year window, Common Equity tumbled 103.53% in 2024 and soared 13839.08% in 2025, its largest moves.
• Year by year, Common Equity stood at $21.0 million in 2022, then sank by 47.81% to $11.0 million in 2023, then surged by 764.16% to $94.9 million in 2024, then surged by 82.26% to $172.9 million in 2025, then retreated by 3.06% to $167.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $167.6 million in Q1 2026, $172.9 million in Q4 2025, and $72.9 million in Q3 2025.